From the Guidelines
Oligomenorrhea, or light and infrequent menstrual periods, is not a direct cause of infertility, but it can be associated with underlying conditions that affect fertility, such as polycystic ovary syndrome (PCOS) or hormonal imbalances, as noted in the 2020 study on female infertility 1.
Understanding Oligomenorrhea and Infertility
The relationship between oligomenorrhea and infertility is complex. While oligomenorrhea itself does not directly cause infertility, conditions that lead to oligomenorrhea, such as PCOS, can significantly impact fertility. PCOS is a leading cause of anovulatory infertility, affecting at least 7% of adult women 1.
Diagnostic Considerations
For women experiencing oligomenorrhea and difficulty conceiving, a comprehensive evaluation is necessary. This may include tracking ovulation, hormone level assessments, and imaging studies like ultrasound to evaluate ovarian reserve and detect conditions such as polycystic ovarian morphology (PCOM) or endometriosis, which can affect fertility 1.
Importance of Evaluation
Given that infertility affects about 15.5% of women and can be due to various factors including ovulatory disorders, tubal damage, and unexplained causes 1, a thorough investigation is crucial for women with oligomenorrhea who are trying to conceive. This is particularly important for women over 35, where the likelihood of infertility increases, and investigations should be initiated after 6 months of unprotected intercourse without pregnancy 1.
Conclusion on Approach
Therefore, while oligomenorrhea is not a direct indicator of infertility, its presence, especially when combined with difficulty conceiving, warrants a detailed fertility evaluation to identify and address any underlying conditions that may be impacting fertility, as guided by the most recent and highest quality evidence available 1.
From the FDA Drug Label
Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.
The FDA drug label does not answer the question.